Vector Labs Ab02210-10.3 Anti-CD19 [B4], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: B4
Heavy Chain Modification: Fc Silent™
Synonyms: B4 antigen; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12
Amount: 200 μg
Application Codes Clone: IF; FC; IHC
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody reacts with the B4 antigen present on the peripheral blood cells and lymphoid organs, on cell lines derived from normal and malignant B cells, and on tumor cells isolated from patients with B cell-derived neoplasms
Application Notes: This antibody is recommended to be used for the cell surface expression of the B4 antigen. It is reported that in mitogen stimulated B cells the expression of the B4 antigen increases initially with the B cell activation and then is lost with the B cell differentiation (PMID: 6408173). Conjugate of DC1 with murine and humanizsed versions of anti-B4 antibody was found to be potent and effective in selective killing of target cells in culture. It is also reported that the anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals hearing large tumors (PMID: 7545085). Anti-B4 when conjugated with blocked ricin increased the antibody induced cell calcium mobilization and CD19 internalization. Modulation of CD19 induced by anti-B4 or anti-B4–bR was evaluated by indirect immunofluoresecence and flow cytometry (PMID: 9310487). Anti-B4-blocked ricin (anti-B4-bR) recognizes CD19-positive cells, which includes most B-cell non-Hodgkin’s lymphomas (NHLs). Phase II clinical studies of anti-B4-bR suggested that it does not actively penetrate in certain sites of the disease and is not an active agent in relapsed NHLs (PMID: 9829722)

Product Class:	Purified
Clone ID:	B4
Heavy Chain Modification:	Fc Silent™
Synonyms:	B4 antigen; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12
Amount:	200 μg
Application Codes Clone:	IF; FC; IHC
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody reacts with the B4 antigen present on the peripheral blood cells and lymphoid organs, on cell lines derived from normal and malignant B cells, and on tumor cells isolated from patients with B cell-derived neoplasms
Application Notes:	This antibody is recommended to be used for the cell surface expression of the B4 antigen. It is reported that in mitogen stimulated B cells the expression of the B4 antigen increases initially with the B cell activation and then is lost with the B cell differentiation (PMID: 6408173). Conjugate of DC1 with murine and humanizsed versions of anti-B4 antibody was found to be potent and effective in selective killing of target cells in culture. It is also reported that the anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals hearing large tumors (PMID: 7545085). Anti-B4 when conjugated with blocked ricin increased the antibody induced cell calcium mobilization and CD19 internalization. Modulation of CD19 induced by anti-B4 or anti-B4–bR was evaluated by indirect immunofluoresecence and flow cytometry (PMID: 9310487). Anti-B4-blocked ricin (anti-B4-bR) recognizes CD19-positive cells, which includes most B-cell non-Hodgkin’s lymphomas (NHLs). Phase II clinical studies of anti-B4-bR suggested that it does not actively penetrate in certain sites of the disease and is not an active agent in relapsed NHLs (PMID: 9829722)

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews